Research Radboud technology centers Radboud Biobank News Opt-out versus Opt-In Consent for Residual Samples
17 October 2019

The Blue Diamond Gallery Residual samples, i.e. biomaterial leftover from standard clinical procedures, constitute a critical resource for the biobanking community.

Residual material refers to biomaterials leftover from standard clinical procedures as well as clinical imaging and associated medical data. These types of samples are critical for biobanking research and education within the Radboudumc. To date, the hospital has relied on an opt-out method of consent, which means samples are available for scientific research unless a patient explicitly objects. The Radboud Biobank will be conducting a 6-month feasibility study, as proposed by the Netherlands Federation of University Medical Centers (NFU), to evaluate the impact of migrating to a opt-in method, which requires explicit consent from the patient for use of the residual material. This feasibility study will be restricted to new patients (approximately 500 per week) and will exclude those who are comatose, incapacitated, <16 years of age, or admitted for acute care. Eligible new patients will be asked for their consent while registering at the Central Registration Desk. Their responses will be immediately recorded in their Electronic Health Record (Epic). Patients who are unable to decide during their registration will be contacted by a Radboud Biobank representative within two weeks to clarify concepts and answer remaining questions. All patients will be able to withdraw their consent in their personal electronic chart (MijnRadboud). At pre-defined points during the feasibility study, the Radboud Biobank will examine the distribution of responses by key sociodemographic characteristics to explore obstacles in an opt-in consent process. For more information on the use of residual material in the Radboudumc, please visit the Radboud Biobank website. There is also a poster available with more information.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Sub-biobank MEMORY

15 September 2020

The MEMORY biobank focuses on research into biomarkers for memory impairment and dementia and their validation in clinical cohorts.

read more

RYR1 sub-biobank

15 September 2020

The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants.

read more

New colleague

15 September 2020

My name is Robbert Croes and I started mid 2020 as a data-scientist at the Radboud Biobank.

read more

ProBCI sub-biobank

15 September 2020

There is a pressing need for predictive biomarkers to personalize bladder cancer treatment.

read more

Financial regulation for sub-biobanks

15 September 2020

Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.

read more